GlucoseCon Cancer Research Results

GlucoseCon, Glucose Consumption: Click to Expand ⟱

Source:

Type:

Glucose consumption is often elevated in cancer cells due to an increased reliance on glycolysis for energy production, even in the presence of oxygen. This phenomenon, known as the Warburg effect, is a metabolic shift that allows cancer cells to rapidly proliferate and survive in nutrient-poor environments.

The increased glucose consumption in cancer cells can be detected using positron emission tomography (PET) scans, which measure the uptake of a glucose analog labeled with a radioactive tracer.

BC, Breast Cancer: Click to Expand ⟱

Breast Cancer

Scientific Papers found: Click to Expand⟱

3434-

ALA,

Alpha lipoic acid modulates metabolic reprogramming in breast cancer stem cells enriched 3D spheroids by targeting phosphoinositide 3-kinase: In silico and in vitro insights

in-vitro,

BC,

MCF-7

in-vitro,

BC,

MDA-MB-231

tumCV↓, PI3K↓, p‑Akt↓, p‑P70S6K↓, mTOR↓, ATP↓, GlucoseCon↓, ROS↑, PKM2↓, LDHA↓, Glycolysis↓, ChemoSen↑,

3436-

ALA,

Alpha lipoic acid modulates metabolic reprogramming in breast cancer stem cells enriched 3D spheroids by targeting phosphoinositide 3-kinase: In silico and in vitro insights Author links open overlay panel

in-vitro,

BC,

MCF-7

ChemoSen↑, PI3K↓, Akt↓, ATP↓, GlucoseCon↓, ROS↑, PKM2↓, Glycolysis↓, CSCs↓, IGF-1R↓, Furin↓, RadioS↑,

3454-

ALA,

Lipoic acid blocks autophagic flux and impairs cellular bioenergetics in breast cancer and reduces stemness

in-vitro,

BC,

MCF-7

(0.5 mM, 1 mM, 2.5 mM, and 5 mM)

in-vitro,

BC,

MDA-MB-231

TumCG↑, Glycolysis↓, ROS↑, CSCs↓, selectivity↑, LC3B-II↑, MMP↓, mitResp↓, ATP↓, OCR↓, NAD↓, p‑AMPK↑, GlucoseCon↓, lactateProd↓, HK2↓, PFK↓, LDHA↓, eff↓, mTOR↓, ECAR↓, ALDH↓, CD44↓, CD24↓,

2388-

Ash,

Withaferin A decreases glycolytic reprogramming in breast cancer

in-vitro,

BC,

MDA-MB-231

5 μM WA

in-vitro,

BC,

MDA-MB-468

in-vitro,

BC,

MCF-7

in-vitro,

BC,

MDA-MB-453

GlucoseCon↓, lactateProd↓, ATP↓, Glycolysis↓, GLUT1↓, HK2↓, PKM2↓, cMyc↓, Warburg↓, cMyc↓,

2707-

BBR,

Berberine exerts its antineoplastic effects by reversing the Warburg effect via downregulation of the Akt/mTOR/GLUT1 signaling pathway

in-vitro,

Liver,

HepG2

concentrations >25 µM after 48 h

in-vitro,

BC,

MCF-7

GLUT1↓, Akt↓, mTOR↓, ATP↓, GlucoseCon↓, TumCP↓, Warburg↓, selectivity↑, TumCCA↑, Glycolysis↓,

943-

BetA,

Betulinic acid suppresses breast cancer aerobic glycolysis via caveolin-1/NF-κB/c-Myc pathway

in-vitro,

BC,

MCF-7

in-vitro,

BC,

MDA-MB-231

in-vivo,

NA,

mouse model

Glycolysis↓, lactateProd↓, GlucoseCon↓, ECAR↓, cMyc↓, LDHA↓, p‑PDK1↓, PDK1↓, Cav1↑, *Glycolysis↑, selectivity↑, OCR↓, OXPHOS↓,

2727-

BetA,

Betulinic acid in the treatment of breast cancer: Application and mechanism progress

Review,

BC,

mt-ROS↑, Sp1/3/4↓, TumMeta↓, GlucoseCon↓, NF-kB↓, ChemoSen↑, chemoP↑, m-Apoptosis↑, TOP1↓,

2304-

CUR,

Curcumin decreases Warburg effect in cancer cells by down-regulating pyruvate kinase M2 via mTOR-HIF1α inhibition

in-vitro,

Lung,

H1299

0–20 μM curcumin for 24

in-vitro,

BC,

MCF-7

in-vitro,

Cerv,

HeLa

in-vitro,

Pca,

PC3

in-vitro,

Nor,

HEK293

Glycolysis↓, GlucoseCon↓, lactateProd↓, PKM2↓, mTOR↓, Hif1a↓, selectivity↑, Dose↝, tumCV↓,

951-

DHA,

Docosahexaenoic Acid Attenuates Breast Cancer Cell Metabolism and the Warburg Phenotype by Targeting Bioenergetic Function

in-vitro,

BC,

BT474

25-100uM

in-vitro,

BC,

MDA-MB-231

in-vitro,

Nor,

MCF10

Hif1a↓, GLUT1↓, LDH↓, GlucoseCon↓, lactateProd↓, ATP↓, p‑AMPK↑, ECAR↓, OCR↓, *toxicity↓,

681-

EGCG,

Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models

vitro+vivo,

BC,

10-320 μM

Casp3↑, Casp8↑, Casp9↑, TumAuto↑, Beclin-1↝, ATG5↝, GlucoseCon↓, lactateProd↓, ATP↝, HK2↓, LDHA↓, Hif1a↓, GLUT1↓, TumVol↓, VEGF↓,

960-

HNK,

Honokiol Inhibits HIF-1α-Mediated Glycolysis to Halt Breast Cancer Growth

vitro+vivo,

BC,

MCF-7

HNK (diluted in DMSO, 25 mg/kg/day

mice

vitro+vivo,

BC,

MDA-MB-231

0-40uM/24hr

OCR↑, ECAR↓, GlucoseCon↓, lactateProd↓, ATP↓, Glycolysis↓, Hif1a↓, GLUT1↓, HK2↓, PDK1↓, Apoptosis↑, LDHA↓,

2456-

MET,

Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer

in-vitro,

BC,

MDA-MB-231

in-vivo,

NA,

GlucoseCon↓, TumCG↓, HK2↓, p‑AMPK↑, TXNIP↓, *toxicity↓,

968-

OA,

Oroxylin A inhibits glycolysis-dependent proliferation of human breast cancer via promoting SIRT3-mediated SOD2 transcription and HIF1α destabilization

vitro+vivo,

BC,

MDA-MB-231

mice

in-vitro,

BC,

MBT-2

Hif1a↓, SIRT3↑, SOD2↑, GlucoseCon↓, Glycolysis↓, TumCG↓,

2452-

PA,

Targeting Pyruvate Kinase M2 and Hexokinase II, Pachymic Acid Impairs Glucose Metabolism and Induces Mitochondrial Apoptosis

in-vitro,

BC,

SkBr3

HK2↓, GlucoseCon↓, lactateProd↓, mtDam↑, ATP↓, ROS↑, PKM2↑,

2409-

PTS,

Pterostilbene Induces Pyroptosis in Breast Cancer Cells through Pyruvate Kinase 2/Caspase-8/Gasdermin C Signaling Pathway

in-vitro,

BC,

EMT6

 0, 20, 40, 60, and 80 µM of PTE for 24, 48, and 72 h

in-vitro,

BC,

4T1

in-vitro,

Nor,

HC11

Pyro↑, Glycolysis↓, *toxicity∅, selectivity↑, GSDMC↑, PKM2↓, PKM1↑, GlucoseCon↓, lactateProd↓, ATP↓, TumCG↓,

2341-

QC,

Quercetin suppresses the mobility of breast cancer by suppressing glycolysis through Akt-mTOR pathway mediated autophagy induction

in-vitro,

BC,

MCF-7

30Î¼M

in-vitro,

BC,

MDA-MB-231

in-vivo,

NA,

intraperitoneally injected with 50 mg/kg quercetin twice daily for a
month

mice

MMP2↓, MMP9↓, VEGF↓, Glycolysis↓, lactateProd↓, PKM2↓, GLUT1↓, LDHA↓, TumAuto↑, Akt↓, mTOR↓, TumMeta↓, MMP3↓, eff↓, GlucoseCon↓, lactateProd↓, TumAuto↑, LC3B-II↑,

2328-

RES,

Resveratrol Inhibits Cancer Cell Metabolism by Down Regulating Pyruvate Kinase M2 via Inhibition of Mammalian Target of Rapamycin

in-vitro,

Cerv,

HeLa

50 µM resveratrol for 48 hour

in-vitro,

Liver,

HepG2

in-vitro,

BC,

MCF-7

PKM2↓, mTOR↓, GlucoseCon↓, lactateProd↓,

2181-

SK,

Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2

in-vitro,

BC,

MCF-7

0-20uM for 1 h

0.3 mM,

in-vitro,

Lung,

A549

in-vitro,

Cerv,

HeLa

Glycolysis↓, lactateProd↓, GlucoseCon↓, PKM2↓, LDH∅,

2414-

β‐Ele,

Beta‐elemene inhibits breast cancer metastasis through blocking pyruvate kinase M2 dimerization and nuclear translocation

in-vitro,

BC,

MDA-MB-231

in-vitro,

BC,

MCF-7

in-vivo,

NA,

mice

TumCMig↓, TumCI↓, TumMeta↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, PKM2↓, EGFR↓, GLUT1↓, LDHA↓, ECAR↓, OCR↓,

Showing Research Papers: 1 to 19 of 19

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 19

Pathway results for Effect on Cancer / Diseased Cells:

Functional Outcomes ⓘ

chemoP↑, 1, TumVol↓, 1,
Total Targets: 82

Pathway results for Effect on Normal Cells:

Core Metabolism/Glycolysis ⓘ

Glycolysis↑, 1,

Functional Outcomes ⓘ

toxicity↓, 2, toxicity∅, 1,
Total Targets: 3

Scientific Paper Hit Count for: GlucoseCon, Glucose Consumption

3 Alpha-Lipoic-Acid
2 Betulinic acid
1 Ashwagandha(Withaferin A)
1 Berberine
1 Curcumin
1 Docosahexaenoic Acid
1 EGCG (Epigallocatechin Gallate)
1 Honokiol
1 Metformin
1 Oroxylin-A
1 Pachymic acid
1 Pterostilbene
1 Quercetin
1 Resveratrol
1 Shikonin
1 β‐Elemene

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:4  Cells:%  prod#:%  Target#:623  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

GlucoseCon Cancer Research Results

Pathway results for Effect on Cancer / Diseased Cells:

Redox & Oxidative Stress ⓘ

Mitochondria & Bioenergetics ⓘ

Core Metabolism/Glycolysis ⓘ

Cell Death ⓘ

Kinase & Signal Transduction ⓘ

Transcription & Epigenetics ⓘ

Autophagy & Lysosomes ⓘ

Cell Cycle & Senescence ⓘ

Proliferation, Differentiation & Cell State ⓘ

Migration ⓘ

Angiogenesis & Vasculature ⓘ

Barriers & Transport ⓘ

Immune & Inflammatory Signaling ⓘ

Drug Metabolism & Resistance ⓘ

Clinical Biomarkers ⓘ

Functional Outcomes ⓘ

Pathway results for Effect on Normal Cells:

Core Metabolism/Glycolysis ⓘ

Functional Outcomes ⓘ

Home Page